Biostem Technologies (BSEM) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $74.5 million and first half revenue of $116.4 million, a dramatic increase from $1.6 million in the same period last year, driven by strong commercial performance of AmnioWrap2 and BioRetain products.

• Net income for Q2 2024 was $6.4 million, with first half net income at $9.6 million, compared to losses in the prior year.

• Gross margin remained robust at 95% in Q2 2024, with gross profit for the first half at $110.4 million.

• Strategic priorities include launching clinical trials, publishing peer-reviewed data, and preparing for changes in reimbursement landscape.

• Announced plans to become a fully reporting SEC entity and uplist to NASDAQ, with application and Form 10 filing in progress.

Financial highlights

• Q2 2024 net revenue was $74.5 million, up from $1.0–$1.1 million in Q2 2023; six-month revenue was $116.4 million, up from $1.6 million.

• Gross profit for Q2 was $70.7 million (95% of revenue); first half gross margin was 94.9%.

• Operating expenses rose to $61.9 million in Q2, mainly from workforce expansion, service fees, and share-based compensation.

• Adjusted EBITDA for Q2 was $10 million (13–13.4% of net sales); first half adjusted EBITDA was $17.9 million.

• Cash at June 30, 2024 was $6.6 million, up from $239K at year-end.

Outlook and guidance

• Management expects continued robust results and revenue growth, focusing on product innovation, market expansion, and M&A opportunities.

• Plans to expand clinical trials for AmnioWrap2 and VENDAJE, targeting diabetic foot ulcers and other wound types.

• Anticipates increased R&D spending to mid-single digits as a percentage of net revenue.

• Expansion of manufacturing capacity underway to support future sales growth.